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Abstract
Background: Podocyte specific proteins are dysregulated in diabetic nephropathy, though the extent of their expression
loss is not identical and may be subject to different regulatory factors. Quantifying the degree of loss may help identify the
most useful protein to use as an early biomarker of diabetic nephropathy.
Methodology/Principal Findings: Protein expression of synaptopodin, podocin and nephrin were quantified in 15 Type 2
diabetic renal biopsies and 12 control patients. We found statistically significant downregulation of synaptopodin
(P,0.0001), podocin (P=0.0002), and nephrin (P,0.0001) in kidney biopsies of diabetic nephropathy as compared with
controls. Urinary nephrin levels (nephrinuria) were then measured in 66 patients with Type 2 diabetes and 10 healthy
controls by an enzyme-linked immunosorbent assay (Exocell, Philadelphia, PA). When divided into groups according to
normo-, micro-, and macroalbuminuria, nephrinuria was found to be present in 100% of diabetic patients with micro- and
macroalbuminuria, as well as 54% of patients with normoalbuminuria. Nephrinuria also correlated significantly with
albuminuria (rho=0.89, p,0.001), systolic blood pressure (rho=0.32, p=0.007), and correlated negatively with serum
albumin (rho=20.48, p,0.0001) and eGFR (rho=20.33, p=0.005).
Conclusions/Significance: These data suggest that key podocyte-specific protein expressions are significantly and
differentially downregulated in diabetic nephropathy. The finding that nephrinuria is observed in a majority of these
normoalbuminuric patients demonstrates that it may precede microalbuminuria. If further research confirms nephrinuria to
be a biomarker of pre-clinical diabetic nephropathy, it would shed light on podocyte metabolism in disease, and raise the
possibility of new and earlier therapeutic targets.
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Introduction
Diabetes affecting the kidney, or diabetic nephropathy (DN),
affects approximately one third of patients with either Type 1 or
Type 2 diabetes mellitus [1]. Given the epidemic of new patients
projected to have diabetes by year 2050, the prevalence of DN will
rise just as dramatically [1]. Thus, the only feasible way to tackle
this health care crisis is by prevention of disease with early
detection.
Small amounts of albumin in the urine, or microalbuminuria is
the current early biomarker. However, its association with
progression to renal failure is unclear, as microalbuminuria does
not always lead to progressive renal failure [2]. Furthermore, it is
found in other disease states such as urinary tract infection [3] and
hemodynamic stress (exercise, fever, congestive heart failure) [4,5].
We now know that much of the early inciting events stem from
podocyte pathology. The podocyte is a specialized visceral
epithelial cell that helps to establish the glomerular filtration
barrier and prevents protein loss, along with the glomerular
basement membrane and the endothelial cell layer. Occurrence of
podocytopenia (decreased number) and podocyturia (podocytes in
urine) in DN are well established [6–8]. Podocyte loss initiates the
process of glomerulosclerosis by accelerating synechiae between
podocytes and the glomerular basement membrane. Both the
highly specialized cytoskeleton and its complex slit diaphragm
contribute to the glomerular filtration barrier. Derangement of
either aspect leads to proteinuria [9–11]. In DN, altered
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podocin [13–15] and nephrin have been described [16–18].
Synaptopodin, a proline rich protein, directly interacts with the
a-actinin-induced actin filaments. Downregulation of synaptopo-
din expression leads to structural and functional changes such as
loss of stress fibers, aberrant formation of filopodia, and impaired
cell migration [19,20]. Nephrin and podocin, on the other hand,
are slit-diaphragm associated proteins. Nephrin, being a trans-
membrane protein with an extracellular and intracellular domain,
forms the scaffolding of the podocyte slit diaphragm. It is linked to
the actin cytoskeleton via podocin and CD2AP. These proteins not
only characterize the differentiated phenotype of the podocyte but
have also been identified to have functional characteristics as they
interact with the PI3K/AKT signaling pathway to maintain
functional integrity [21]. Mutation of either protein can result in
foot process effacement and massive proteinuria [22,23]. Given
their dysregulation in DN, podocytes and their specific proteins
pose as attractive candidates as either diagnostic or predictor
biomarkers of disease. Patari et al. has described presence of
nephrin in the urines of Type I diabetic patients even in the
absence of microalbuminuria [24], while Nakamura et al.
discovered urinary podocytes only in patients with micro- and
macroalbuminuria, not normoalbuminuria [8]. However, there is
little information in Type 2 diabetic patients, which make up the
majority of patients who progress to end-stage renal disease.
In the current study, we investigated the morphologic
alterations of podocyte-specific proteins in DN biopsies from
patients with Type 2 diabetes and found significant downregula-
tion of synaptopodin, podocin and nephrin expression in the
diabetic group as compared to controls. Given the availability of a
reliable method of quantifying nephrin in the urine (nephrinuria),
we measured its levels in diabetic patients and found that it was
detected in 54% of normoalbuminuric patients, suggesting its
potential role as an early biomarker.
Methods
Objectives
Our goal is to study the expression of podocyte specific proteins
in renal biopsies of Type 2 diabetic patients, and then to select the
most downregulated protein as a marker for early detection of
renal disease.
Participants
Biopsy samples. Study samples consisted of kidney biopsies
of 15 DN patients that were obtained at Jacobi Medical Center in
Bronx, New York, USA and archived at Columbia-Presbyterian
Hospital in New York, New York, USA. Indications for biopsy
included: presence of nephrotic syndrome without retinopathy,
unexplained acute kidney injury, or presence of hematuria. All
clinical data at time of biopsy were retrieved from electronic
medical records at Jacobi Medical Center. Twelve control biopsies
consisted of normal kidney tissue from tumor nephrectomies. This
study has been approved by the Internal Review Board of the
Albert Einstein College of Medicine.
Urine collection. Patients were selected from the outpatient
nephrology clinic at Jacobi Medical Center. A one-time random
urine sample was collected by the clean catch method on all study
and control subjects. Inclusion criteria for study patients were:
history of type 2 diabetes, absence of another renal or urinary tract
disease, and absence of pregnancy. There were no exclusion
criteria based on race, age, or gender. Diabetic patients were
categorized as having normoalbuminuria when urine albumin-to-
creatinine ratio (UACR) ,30 mg/g, microalbuminuria when
UACR was between 30 and 300 mg/g, and macroalbuminuria
when UACR was .300 mg/g. All control subjects were healthy
volunteers from the medical staff with no history of diabetes,
hypertension, or renal disease. Demographic and clinical data
were recorded, including age, sex, weight, height, medications,
blood pressure, blood urea nitrogen (BUN), serum creatinine,
HbA1C, random urine albumin, urine creatinine, and urine
protein. All clinical laboratories values were measured at the
Department of Clinical Laboratories at Jacobi Medical Center.
Estimated glomerular filtration rate (eGFR) was calculated by the
4-variable Modification of Diet in Renal Disease study equation
[25]. This study has been approved by the Internal Review Board
of the Albert Einstein College of Medicine.
Description of Procedures or Investigations undertaken
Immunohistochemistry. Paraffin-embedded tissues sections
were deparaffinized in microwave oven for 3 minutes. The
sections were rehydrated in graded series of xylene and alcohols.
Endogenous peroxidase activity was blocked by 3% hydrogen
peroxide in distilled water for 15 minutes. Antigen retrieval was
achieved by steam heating in a solution of citrate buffer, pH 6.0
for 30 minutes. Sections were blocked with 10% normal horse
serum for monoclonal antibodies and 10% normal goat serum for
polyclonal antibodies. Sections were then incubated overnight
with primary antibodies monoclonal mouse anti-human synapto-
podin antibody (1:20) (gift of Dr. Peter Mundel), polyclonal rabbit
anti-human podocin antibody (1:1000) (gift of Dr. Peter Mundel),
monoclonal mouse anti-human nephrin antibody (1:50) (gift of Dr.
Karl Tryggvason), and polyclonal rabbit anti-human nephrin
antibody (1:200) (Enzo Life Sciences Inc., Farmingdale, NY) at
4uC. Horse anti-mouse IgG and goat anti-rabbit IgG (Dako Inc.
Carpinteria, CA) were used as secondary antibodies (1:1000) for
30 minutes. The sections were then incubated in avidin-biotin
complex at 1:25 dilution (Vector Labs, Burlingame, CA) and
developed using diaminobenzidine (DAB) as chromogen. After
washing, the sections were counter-stained with hematoxylin and
coverslipped. Negative controls were carried out by incubation in
the absence of the primary antibody.
Morphometry. Areas of positive DAB staining as a percent-
age of the entire glomerulus were calculated using the ImageJ
software (US National Institutes of Health) for each glomerulus in
the biopsy sample. Subsequently, a mean value of positive DAB
staining was calculated based on the number of glomeruli for each
biopsy sample.
Enzyme-linked immunosorbent assay. Urinary nephrin
was determined by a competitive enzyme-linked immunosorbent
assay, using polyclonal antibodies against the extracellular domain
(amino acids 23–322) of human nephrin (Exocell Inc., Philadel-
phia, PA). The assay was performed by Exocell Inc. according to
manufacturer’s instructions. Briefly, urine samples were diluted in
the range of 1:10 to 1:500 (depending on degree of proteinuria in
urines sample). A 50-ml diluted sample was added to each well
already coated with rat nephrin followed by the addition of a 50-ml
of rabbit anti-nephrin antibody for an incubation of 60 minutes at
room temperature. Plates were washed followed by the incubation
with 100-ml of anti-rabbit HRP conjugate to each well for
60 minutes. After plates were washed and color developed,
absorbance was read at 450 nm. Elevated levels of urinary
nephrin or nephrinuria was defined as urine nephrin-creatinine
ratio (UNCR) (mg/g) $0.1 mg/g. This value was based on 10
healthy controls who consistently exhibited UNCR ,0.1 mg/g.
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Archival human kidney biopsies and random urine samples
were collected at Jacobi Medical Center, Bronx, New York as part
of exempted protocols ‘‘Differential Protein Expression in
Nephrotic Diseases’’ and ‘‘Analysis of Urinary Proteins in
Nephrotic Syndrome’’, both of which were approved by the
Institutional Review Board of the Albert Einstein College of
Medicine of Yeshiva University. Since all clinical data were de-
identified, no consent was required.
Statistical methods (if applicable)
Analyses were performed comparing study and control biopsies
and also between 4 groups defined as normal controls (no
diabetes), normo-, micro-, and macroalbuminuria. Categorical
variables were presented as percentage while continuous variables
were presented as median (interquartile range) or mean 6
standard deviation (SD) if normality assumptions were not
substantially violated. Differences between mean rank expression
of proteins between study and control biopsies were calculated
using Mann-Whitney test. Difference in UNCR between groups
was determined Kruskal-Wallis. Spearman correlations were
calculated to assess trend for continuous variables and Chi-square
was used to assess associations of categorical variables. Both
UACR and UNCR were log transformed for graphical depiction.
Analyses were performed with STATA Version 8.2 and GraphPad
Prism Version 5.0 for Windows software and results were
considered statistically significant if P,0.05.
Results
Synaptopodin, podocin, and nephrin expression are
significantly decreased in DN as compared to controls
Clinical characteristics of diabetic and control patients are
summarized in Table 1. Of the 15 biopsies, 14 had pathologic
findings of moderate to severe nodular diabetic glomerulosclerosis,
the remaining included 1 with diffuse diabetic glomerulosclerosis
Figure 1. Synaptopodin, podocin, and nephrin are significantly downregulated in diabetic nephropathy (DN) as compared to
controls (Con). Representative staining of synaptopodin in Con (A), DN (B), podocin in Con (E) and DN (F), and nephrin in Con (I) and DN (J).
Negative controls without administration of primary antibody are represented for synaptopodin (C), podocin (G), and nephrin (K). Quantification of
synaptopodin (D), podocin (H), and nephrin (L) positive area per glomerular tuft in Con (12 patients) and DN (15 patients). Horizontal lines represent
the median value. *Number of DN biopsies for nephrin was 11 due to lack of remaining tissue.
doi:10.1371/journal.pone.0036041.g001
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evidence of both arteriosclerosis and arteriolosclerosis, and 12
biopsies had tubular atrophy and interstitial fibrosis. All but 2 of
the diabetic biopsy patients had nephrotic range proteinuria.
Control biopsies revealed intense linear staining of synaptopodin,
podocin and nephrin in podocytes along the capillary walls
(Fig. 1A, E, I). Diabetic biopsies, on the other hand, demonstrated
granular, discontinuous staining with areas of absent expression of
synaptopodin, podocin, and nephrin (using antibody from Enzo
LifeSciences, Inc.) (Fig. 1B, F, J). Consistent results were found
when nephrin antibody from Dr. Karl Tryggvason was used (data
not shown). When quantified, synaptopodin, podocin, and nephrin
expression were significantly decreased in DN, despite exhibiting
glomerulomegaly, as compared with control biopsies (Fig. 1D, H,
L). Negative controls without administration of primary antibody
is represented for each antibody (1, C, G, K).
Nephrinuria detected in patients with normoalbuminuria
We subsequently measured urinary nephrin in 66 diabetic
patients of all chronic kidney disease (CKD) stages and levels of
albuminuria and compared them to 10 healthy control subjects.
Clinical characteristics are summarized in Table 2. There were 26
Table 1. Clinical characteristics of control and Type 2 diabetic nephropathy patients.
Clinical Characteristic Control (n=12)
Diabetic Nephropathy
(n=15) P value
Age (years) 56 (52;60) 56 (51.9;63.5) 0.83
Male sex (%) 75% 66% 0.67
Urine protein-to-creatinine
ratio (g/g)
–* 5.3 (3.9;7.8) –
Blood urea nitrogen (mg/dL) 15 (12.8;17.3) 51 (39.5;63.3) ,0.0001
Serum creatinine (mg/dl) 1.0 (0.8;1.1) 4.1 (2.7;4.8) 0.0005
estimated GFR (ml/min/1.73 m
2) 86.8 (61.8;103.7) 13.35 (12.5;40.7) 0.0008
Serum albumin (g/dl) 4.2 (3.7;4.4) 2.5 (2.3;3.6) 0.0002
Systolic blood pressure mm/Hg 127 (120;130) 150 (140;166) 0.0002
Diastolic blood pressure (mm/Hg) 80.5 (73.4;86.2) 85 (76;91) 0.49
HbA1C% 6.5 (4.5;10.9) 9.3 (7.8;11.8) 0.10
ACEI
{ (%) 25% 73% 0.026
ARB
{ (%) 8.3% 26% 0.25
Data are presented as median (interquartile range) for continuous variables and % for categorical variables.
*Urine protein-creatinine ratio not available for control patients as their urinalyses did not show proteinuria.
{ACEI: angiotensin converting enzyme inhibitors.
{ARB: angiotensin receptor blockers.
doi:10.1371/journal.pone.0036041.t001
Figure 2. Correlations between urine nephrin-to-creatinine ratio (UNCR) and clinical markers of renal disease. A) Log transformed
UNCR correlates significantly with macroalbuminuria (rho=0.82, p,0.0001) and microalbuminuria (rho=0.66, p=0,02), and not significantly with
normoalbuminuria (rho=0.34, p=0.09) when divided into groups according to level of albuminuria.
doi:10.1371/journal.pone.0036041.g002
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uria, and 29 patients with macroalbuminuria. A significant
difference in median urine nephrin-to-creatinine ratio (UNCR)
was observed between control subjects and all diabetic categories
(p,0.0001) (Table 2). In addition, nephrinuria was detected in
54% of normoalbuminuric patients. UNCR also did not differ
significantly from those treated and those not treated with
angiotensin converting enzyme inhibitors or angiotensin receptor
blockers amongst subgroups of normo-, micro-, and macroalbu-
minuria (p=0.68, 0.62, and 0.32 respectively). We found the
highest correlation between UNCR levels with albuminuria
(rho=0.89, p,0.001), serum creatinine (rho=0.43, p=0.0002),
BUN (rho=0.37, p=0.001) and systolic blood pressure (rho=0.32,
p=0.007) (Table 3). UNCR showed negative correlations with
serum albumin (rho=20.48, p,0.0001) and eGFR (rho=20.33,
p=0.005) (Table 3). UNCR also correlated in subgroups of
microalbuminuric (rho=0.66, p=0.02) and macroalbuminuric
(rho=0.82, p,0.001) patients (Figure 2). The correlation in
normoalbuminuic patients (rho=0.34, p=0.09) was not significant
despite a trend in that direction.
Discussion
Our results substantiated the dysregulated podocyte phenotype
in human DN and quantified expressions of synaptopodin,
podocin and nephrin in all Type 2 diabetic biopsies. Decreased
expression of protein and mRNA levels has been described in
podocyte-associated molecules in both animal models [26–29] and
human subjects of DN [12,13,16–18,30,31]. Though significant
decreased expression of these podocyte-specific proteins may have
been anticipated, we found that the extent of loss is not identical,
i.e. these three biomarkers are not interchangeable, suggesting that
they have different regulatory factors. For instance, synaptopodin
is susceptible to cleavage by cathepsin L, a lysosomal enzyme that
is induced in DN [19,32]. Cathepsin L also cleaves the GTPase
dynamin, which has been shown to be essential for podocyte
function [32]. Whether podocin or nephrin are as vulnerable is
unknown at this time.
Furthermore, nephrin may be unique in that it modulates the
podocyte’s response to insulin. Coward et al. has shown that
Table 2. Clinical parameters of control and type 2 diabetic patients.
Control
n=10
Normo-albuminuria
n=26
Micro-albuminuria
n=11
Macro-albuminuria
n=29 P value
Men (%) 40% 44% 45% 53% 0.85
Age 61612.2 62614 6867.3 59613 ,0.0001
HbA1C – 7.6 (6.5,8.1) 7.2 (6.3,8.0) 7.5 (6.8,9.0) 0.6
UACR
* (mg/g) 7.32 (3.7,14.5) 7.9 (5.6,12.8) 93.8 (79.1,185.4) 1644.3 (750.3,3013.3) ,0.0001
Serum creatinine (mg/dL) 0.9 (0.8,1.0) 1.4 (0.9,1.6) 1.8 (1.5,2.1) 2.1 (1.6,2.9) ,0.0001
estimated GFR (ml/min/
1.73m
2)
89 (65,120) 47 (36.2,72.2) 37 (29,48) 30 (20,44.5) ,0.0001
Systolic blood pressure
(mmHg)
125 (102,149) 132 (120,145) 139 (129,159) 144 (136,154) 0.0001
Diastolic blood pressure
(mmHg)
67 (54,85) 68 (54,76) 70 (64,72) 76 (66,88) 0.21
% Diabetic Retinopathy – 43% 20% 55% 0.15
UNCR
{ (mg/g) 0.07 (.03,.098) 0.11(.08,.17)
1 1.16 (.35,1.60) 9.15 (5.68,12.08) ,0.0001
{
% ACEI/ARB treatment 0% (0/10) 73% (19/26) 54% (6/11) 62% (18/29) 0.0004
{
% UNCR .0.1 (mg/g) 0% (0/10) 54% (14/26) 100% (11/11) 100% (29/29) 0.001
{
Data are means +/2 SD or median (interquartile range).
*UACR: urine albumin-to-creatinine ratio.
{UNCR: urine nephrin-to-creatinine ratio.
{P for trend across the 4 categories.
1P ,0.05 vs. Control.
doi:10.1371/journal.pone.0036041.t002
Table 3. Correlations of urine nephrin-creatinine ratio (UNCR)
with clinical parameters.
Parameter n value Rho P value
UACR* (mg/g) 61 0.89 ,0.001
Serum creatinine
(mg/dL)
65 0.43 0.0002
Blood urea nitrogen
(mg/dL)
65 0.37 0.001
estimated GFR
(ml/min/1.73m
2)
65 20.33 0.005
HbA1C 63 0.20 0.10
Serum albumin
(g/dL)
55 20.48 0.0001
Systolic blood
pressure (mmHg)
64 0.32 0.007
Diastolic blood
pressure (mmHg)
64 0.21 0.07
Presence of diabetic
retinopathy
58 0.14 0.27
Presence of ACEI
{
or ARB
{
66 20.04 0.75
Correlations were determined by calculations of Spearman rho.
*UACR: urine albumin-to-creatinine ratio.
{ACEI: angiotensin converting enzyme inhibitor.
{ARB: angiotensin receptor blocker.
doi:10.1371/journal.pone.0036041.t003
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resistance [33]. Interrupting the fusion of glucose transporters
GLUT4 and GLUT1 to the plasma cell membrane when nephrin
is absent appears to be the mechanism [33]. There also exists
evidence that when podocytes in cell cultures are treated with
angiotensin and glycated albumin (insults relevant to diabetes),
there is shedding of extracellular domain of the nephrin molecule
from podocyte cell surface into the urinary space [17]. Interest-
ingly, insulin resistance in the podocyte alone is adequate to
achieve signs of DN, as demonstrated in a knock out mouse model
of insulin receptor deficiency under normoglycemia [34]. There-
fore, the diabetic milieu may represent a vicious cycle of
hyperglycemia, nephrin loss, podocyte insulin resistance, exacer-
bated hyperglycemia resulting in a severe DN phenotype.
That nephrinuria is seen in early disease (in 54% of patients
with normoalbuminuria) and increases in overt disease (macroal-
buminuria) supports a previous finding by Patari et al. who had
described nephrinuria in one-third of diabetic patients with
normoalbuminuria [24]. In contrast to Patari et al., however, is
our report of a significant correlation between nephrinuria and
albuminuria. Patari et al. has described the presence of similar
levels of nephrinuria in all stages of albuminuria, i.e. normo-,
micro-, newly discovered micro-, and macroalbuminuria. How-
ever, their method of detection for nephrinuria was via Western
blotting, which showed either the presence or absence of nephrin
fragments. They used an antibody that detected parts of the intra-
and extracellular domains of nephrin (amino acids 1031–1055 and
1096–1215). Since the level of nephrinuria was not quantified, it is
not immediately obvious whether there would have been an
association with albuminuria. We, on the other hand, employed
the ELISA method which used an antibody that detected the
extracellular domain of nephrin (amino acids 23–322) which
allowed for quantification of nephrinuria. Thus it is difficult to
compare our results from those of Patari et al. as methodologies of
nephrin measurement were different. Nephrinuria has also shown
a significant association with lower eGFR among normoalbumi-
nuric patients in a Chinese population, suggesting that these
patients are at risk of developing renal insufficiency [35].
Interestingly, a recent study by Zheng et al demonstrated that
urinary mRNA of synaptopodin, podocin, and other podocyte-
specific molecules increased with progression of DN [36]. Though
our study is protein based, our results complement those findings
by demonstrating that urinary nephrin also correlates well with
disease progression and harbors the potential to be an early
biomarker.
Limitations
There are a few limitations to this study. As renal biopsies are
not routinely performed to diagnose DN, these patients may
represent a separate category of patients which may skew podocyte
expression. For example, they may demonstrate a more severe
subset with rapidly progressive renal failure or exhibit concomitant
diagnoses with the presence of hematuria. Our biopsies indicate a
more advanced group of patients, given that the mean eGFR was
27.2 ml/min/1.73 m
2. Unfortunately, it is difficult to avoid this
limitation as it may be unethical to biopsy all classic presentations
of DN, though we used only biopsies that had pathognomonic
findings. Also, since the comparison of nephrinuria with clinical
data was a cross-sectional study, we do not know if nephrinuria is
part of a causal mechanism, or if early nephrinuria will consistently
predict subsequent DN. Measuring nephrinuria prospectively in
diabetic patients with normoalbuminuria will help to answer these
questions, though this type of study will require a prospective study
for at least 10–20 years after onset of diabetes.
In conclusion, we have shown significantly reduced expressions
of synaptopodin and podocin, and nephrin in DN. As a corollary,
we have shown that a high percentage of these patients exhibit
nephrinuria without albuminuria, suggesting its potential utility as
an early biomarker. If further research confirms nephrinuria to be
a biomarker of pre-clinical DN, it would shed light on podocyte
metabolism in disease, and raise the possibility of new and earlier
therapeutic targets.
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